Intellectual PropertyLatest From News

White House considering intellectual property waiver for COVID-19 vaccines  

The White House is considering options for maximising global production and supply of COVID-19 vaccines at the lowest cost, including backing a proposed waiver of intellectual property rights, but no decision has been made, press secretary Jen Psaki said on Tuesday.

Behind this rapid progress are advances in technology and understanding about the nature of the immune system, which have allowed us to more rapidly respond to the current pandemic compared to previous episodes. For instance, it took just a few months to have the first vaccine candidates to test against the coronavirus, compared to 20 months to have a vaccine ready to test in SARS patients a decade ago. Moreover, all of the vaccines that have received EUAs so far rely on groundbreaking platform technology meaning once a genetic target is identified from a new infectious agent, the platform can be used to quickly create prototype vaccines to move into Pre-clinical and clinical testing.

Source: Reuters

 

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button